- Home
- Medical Devices
- Digital Polymerase Chain Reaction (dPCR) Market
Digital Polymerase Chain Reaction (dPCR) Market Size, Share & Trends Estimation Report By Technology(Droplet Digital PCR (ddPCR), BEAMing Digital PCR),By Type(Digital PCR equipment, Consumables and reagents),By Applications(Clinical Diagnostics, Forensic And Others)By End-user(Pharmaceuticals and biotechnology industries, Hospitals and clinical diagnostic centers), By Region, And Segment Forecasts, 2023 - 2030
The Global Digital Polymerase Chain Reaction (dPCR) Market Was Valued At USD 508.82 Million In 2022 And Is Projected To Reach USD 1,305.3 Million By 2030, At A CAGR Of 8.6% From 2022 To 2030.
Digital Polymerase Chain Reaction (dPCR) Market Overview:
Digital PCR is an endpoint PCR method for absolute quantification and analysis of minority sequences in a majority-like context. Digital PCR (dPCR) enables precise, highly sensitive nucleic acid quantification. Conventional PCR is a semi-quantitative end-point assay since amplification products are detected by agarose gel electrophoresis. Real-time PCR (or qPCR) uses fluorescence-based detection to measure the amplification product that accumulates during the reaction. qPCR requires normalization to control or standard curves and only allows relative quantification. Additionally, changes in amplification efficiency may affect qPCR results. Digital PCR (dPCR) is mainly divided into droplet digital PCR, chip digital PCR, and beam digital PCR.
Digital Polymerase Chain Reaction (dPCR) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Digital Polymerase Chain Reaction (dPCR) market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.
Key Market Updates:
- In April 2022, Stilla and Promega Corporation announced a joint marketing agreement to combine sample preparation with the state-of-the-art Maxwell system and digital polymerase chain reaction in the 6-color Naica system. This collaboration strengthened both companies' product portfolios.
- In March 2022, Stila announced partnerships with 12 distributors in the EMEA region. Through this partnership, the company has expanded its presence in the EMEA region.
- In September 2021, Thermo Fisher Scientific Inc. announced the release of the Applied Biosystems QuantStudio Absolute Q digital system.
- In March 2020, Bio-Rad Laboratories, Inc. and lung disease diagnostics company Biodesix, Inc. announced a partnership to provide the COVID-19 droplet digital polymerase chain reaction test to the FDA for Emergency Use Authorization (EUA). I did. These COVID-19-related new product approval partnerships contributed to segment growth in 2020.
Major Segments Covered in the Global Digital Polymerase Chain Reaction (dPCR) Market:
Market Key Players:
Avance Biosciences, Bio-Rad Laboratories, Inc., Fluidigm Corporation, JN medsys, Merck KGAA, Precigenome LLC, QIAGEN N.V, STILLA TECHNOLOGIES, sysmex corporation, Thermo Fisher Scientific, Inc., Formulatrix, Promega, and Others.
Digital Polymerase Chain Reaction (dPCR) Market by Types:
By Technology
- Droplet Digital PCR (ddPCR)
- BEAMing Digital PCR
- Digital PCR equipment
- Consumables and reagents
Digital Polymerase Chain Reaction (dPCR) Market by Applications:
By Applications:
- Clinical Diagnostics
- Forensic And Others
- Research
By End-user
- Pharmaceuticals and biotechnology industries
- Hospitals and clinical diagnostic centers
- University and research organizations
Digital Polymerase Chain Reaction (dPCR) Market by Regions:
The report estimates revenue growth at the worldwide, regional, and country levels and delivers an analysis of the recent industry trends in each sub-segment from 2017 to 2030.
In 2020, North America is expected to dominate the qPCR and dPCR market, followed by Europe. The US holds a dominant share of the North American dPCR and qPCR market due to factors such as the high incidence of chronic and genetic diseases (coupled with the rising geriatric population), growing adoption of qPCR and dPCR techniques in research and academia, significant public-private funding in the field of genome analysis, and the strong presence of major pharmaceutical and biotechnology companies in the country. The US is a well-developed market for genome analysis techniques that are primarily used in clinical applications by healthcare professionals (such as pathogen detection, disease diagnosis, and DNA identification) and research applications by life science researchers (such as genomics and molecular research).
Significant Market Dynamics:
Drivers:
Biomarkers or genomic markers are characteristic molecules such as nucleic acids (including DNA and microRNA or mRNA) that can be detected and quantified in body fluids and tissues. Through the molecular profiling process at the epigenetic, genetic, and protein levels, biomarkers can be a reliable, specific source for understanding disease properties and drug responses. Currently, biomarker analysis is used in diagnostic testing procedures, monitoring treatment effects, and developing new drugs (especially for cancer or cardiovascular diseases). Biomarker analysis uses qPCR and dPCR techniques to detect and quantify genetic material in isolated samples. Over the past decade, biomarker analysis procedures have become increasingly important in the clinical diagnosis and prognosis of diseases, and more and more public and private organizations have focused on research and development to monitor disease progression and develop personalized drugs and treatment regimens. new technology.
Restraints:
Typical qPCR/dPCR methods suffer from multiple technical limitations, such as signal measurement in the exponential phase of the PCR reaction, the need to optimize and validate assay procedures, hinder target detection due to the presence of reaction inhibitors, and failure due to low quality nucleotide templates. Unable to detect target molecule. In addition, qPCR and dPCR reagents have several procedural limitations that directly affect their adoption in genomic research, such as the chemical binding of the reagents to dsDNA (SYBR green dye), the inability to assess DNA quality (AluQuant), and the use of carcinogenic chemicals (Yield gel).
Lab-on-a-chip devices involve the miniaturization and compression of programs into tiny devices. Depending on the field of use, this has several technical advantages. The development of lab-on-a-chip PCR equipment has led to efficient temperature regulation, reduced reagent consumption, and higher sample throughput during analysis. Lab-on-a-chip qPCR is a disruptive technology that has the potential to replace traditional oligonucleotide microarrays. These devices are characterized by low fabrication costs, high throughput, faster detector response, and low sample consumption compared to microarray-based devices. With major advances in the fields of microfluidics and nanotechnology, the development of lab-on-a-chip PCR devices is picking up pace.
Opportunity:
Drug candidates of botanical origin for disease management often belong to chemically similar natural product classes that exhibit nearly identical biological activities and often result in a similar set of therapeutic limitations (side effects, contraindications, dosage limitations, and site of action) . In addition, these natural products may have unknown biological sites of action, resulting in unpredictable biological activities and side effects. The therapeutic limitations of plant-derived drugs can be addressed by gene-based drug candidates with known sites of action (specific genes or proteins).
Challenges:
The main challenges to the widespread adoption and acceptance of qPCR include the tedious preparation and consideration required before performing the actual PCR procedure. These precautions are related to factors such as sample storage conditions, reactant quality, and extraction method. These factors have limited researchers' adoption of MIQE guidelines. Factors such as sample storage conditions, reactant quality, and extraction methods limit researchers' adoption of MIQE guidelines.
Report Scope of Global Digital Polymerase Chain Reaction (dPCR) Market:
Report Attribute | Details |
Study Period | 2017-2030 |
Base Year | 2022 |
Estimated year | 2023 |
Forecast period | 2023-2030 |
Historic Period | 2017-2022 |
Units | Value (USD Billion) |
Growth Rate | CAGR of 8.6% from 2023 to 2030 |
By Technology |
|
By Type |
|
By Applications: |
|
By End-user |
|
By Companies |
Avance Biosciences, Bio-Rad Laboratories, Inc., Fluidigm Corporation, JN medsys, Merck KGAA, Precigenome LLC, QIAGEN N.V, STILLA TECHNOLOGIES, sysmex corporation, Thermo Fisher Scientific, Inc., Formulatrix, Promega, and Others. |
|
|
Reasons to Purchase this Report |
|
Points Covered in the Report
- The points that are discussed within the report are the major market players that are involved in the Market such as Market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
- The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.
- The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
- Data and information by market player, region, type, application and etc., and custom research can be added according to specific requirements.
- The report contains a SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.
Note – In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19 and the Russia-Ukraine war.